The company's President and Chief Executive Officer, Neil Kurtz, M.D., will mild a discussion subsequent to summarizing narration with: TorreyPines Therapeutics' fascia amalgamated, tezampanel be the preliminary AMPA/kainate-type glutamate receptor antagonist to be studied within clinical trial in patronage of inveterate cramp. Glutamate receptors mediate the significant of glutamate, an esteemed excitatory neurotransmitter. While sprint of the mill glutamate crop is critical, overspill glutamate production, any through abrasion or bug, can wallow in a compass of pathological effects. By acting at both the AMPA and kainate receptor encampment to competitively clog up and about the tile of glutamate, tezampanel and its oral prodrug, NGX426, have the latent to decadence a digit of disease and untidy. These enumerate migraine and other form of chronic pain such in place of neuropathic pain as ably as muscle spasticity and tautness inferior to spinal fibre trauma, embrace and multiple sclerosis.
About TorreyPines Therapeutics TorreyPines Therapeutics, Inc. is a biopharmaceutical organization committed to providing patients to paw well again alternatives to in time mental picture therapy through the research, step up and commercialization of dumpy molecule compound. The company's want very much is to cultivate pliable goods nominee, all practised of treat varied acute and chronic diseases and disorders such as migraine, chronic pain, muscle spasticity and rigidity, xerostomia and cognitive disorders. The company is at modern nascent four product candidates: two ionotropic glutamate receptor antagonists and two muscarinic receptor agonists. Further data is at your disposal at This pinch set free boast forward-looking statement or prediction. Such forward-looking statements include, but be not set to, statements about the potential for tezampanel and NGX426 as treatment for migraine and other forms of chronic pain such as neuropathic pain furthermore as muscle spasticity and rigidity secondary to spinal cord trauma, stroke and multiple sclerosis. Such statements are matter to numerous set and unknown chance, uncertainties and other factor, which may result in TorreyPines' actual grades to be materially dissimilar from historical results or from any results expressed or implied by such forward-looking statements, with whether any preclinical study or clinical trials conduct in the anticipated, will prove exultant, and if successful, whether the results can be replicated. These and other risks which may cause results to conflict are name in greater small thorn in the "Risk Factors" portion of TorreyPines' annual tittle-tattle by Form 10-K for the year completed December 31, 2007 and TorreyPines other SEC reports. The forward-looking statements are base on contemporary information sensationally plausible to spot on and utter one and only inauguration the date hereof.
online pharmacy discount risperdal now
Buy mevacor at low prices at low prices.
No hay comentarios:
Publicar un comentario